JOHNSON & JOHNSON |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 149.7 USD | +0.18% |
|
+2.20% | -4.49% |
| 02:06pm | Johnson & Johnson Completes Acquisition of Yellow Jersey Therapeutics | MT |
| Jul. 09 | Mixed feelings |  |
Financials (USD)
| Sales 2024 * | 88.66B | Sales 2025 * | 91.59B | Capitalization | 360B |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 4.11 x |
| Net Debt 2024 * | 4.84B | Net cash position 2025 * | 7.03B | EV / Sales 2025 * | 3.85 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 131,900 |
| Yield 2024 * |
3.23% | Yield 2025 * |
3.37% | Free-Float | 77.08% |
More Fundamentals
* Assessed data
More news
Latest transcript on Johnson & Johnson
More recommendations
More press releases
| 1 day | +0.07% | ||
| 1 week | +2.57% | ||
| Current month | +2.24% | ||
| 1 month | +1.56% | ||
| 3 months | -0.51% | ||
| 6 months | -7.69% | ||
| Current year | -4.66% |
1 week
144.50
149.47
1 month
143.88149.72
Current year
143.13163.58
1 year
143.13175.97
3 years
143.13186.69
5 years
109.16186.69
10 years
81.79186.69
| Managers | Title | Age | Since |
|---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 61 | 88-12-31 |
Joseph Wolk
DFI | Director of Finance/CFO | 57 | 97-12-31 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 58 | 19-11-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marillyn Hewson
BRD | Director/Board Member | 70 | 19-04-24 |
D. Davis
BRD | Director/Board Member | 72 | 14-06-18 |
Anne Mulcahy
BRD | Director/Board Member | 70 | 09-10-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.01% | 208 M€ | +14.51% | - | |
| 12.91% | 21 M€ | +11.76% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-11 | 149.7 | +0.18% | 6 349 627 |
| 24-07-10 | 149.4 | +1.62% | 6,093,187 |
| 24-07-09 | 147 | +1.08% | 5,892,187 |
| 24-07-08 | 145.5 | -0.68% | 5,260,229 |
| 24-07-05 | 146.5 | +0.54% | 4,888,535 |
Delayed Quote Nyse, July 10, 2024 at 04:00 pm EDT
More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Sector
Pharmaceuticals
Calendar
2024-07-17
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
149.4
USD
Average target price
171.7
USD
Spread / Average Target
+14.91%
| 1st Jan change | Capi. | |
|---|---|---|
| -4.66% | 360B | |
| +61.22% | 846B | |
| +40.07% | 628B | |
| +16.77% | 322B | |
| +8.50% | 297B | |
| +14.10% | 240B | |
| +17.76% | 223B | |
| +2.74% | 224B | |
| +11.68% | 173B | |
| -1.53% | 161B |
- Stock Market
- Equities
- JNJ Stock
